Ipsen SA
IPN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€751.00 | Dfwlsx | Syjqjjgk |
Ipsen's Narrow Moat Based on Strong Intangible Assets; FVE EUR 120, Shares Very Undervalued
We've initiated coverage of Ipsen, a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. We assign Ipsen a fair value estimate of EUR 120 per share and view the stock as very undervalued, currently trading in 4-star territory at 25% below our fair value estimate. We believe Ipsen merits a narrow economic moat rating based on its strong intangible assets, a medium uncertainty rating, and a negative moat trend.